AbbVie Inc. 424B5Registration Statements (S-1 / prospectus)

Risk Factors

Risk Factors ​ ​ ​ ​ S-7 ​ ​ USE OF PROCEEDS ​ ​ ​ ​ S-13 ​ ​ CAPITALIZATION ​ ​ ​ ​ S-14 ​ ​ DESCRIPTION OF NOTES ​ ​ ​ ​ S-16 ​ ​ MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS ​ ​ ​ ​ S-39 ​ ​ UNDERWRITING ​ ​ ​ ​ S-44 ​ ​ WHERE TO OBTAIN MORE INFORMATION ​ ​ ​ ​ S-51 ​ ​ INFORMATION INCORPORATED BY REFERENCE ​ ​ ​ ​ S-52 ​ ​ INDUSTRY AND MARKET DATA ​ ​ ​ ​ S-53 ​ ​ FORWARD-LOOKING STATEMENTS ​ ​ ​ ​ S-54 ​ ​ LEGAL MATTERS ​ ​ ​ ​ S-55 ​ ​ EXPERTS ​ ​ ​ ​ S-56 ​ ​ PROSPECTUS ​ ​ ​ Page ​ ABOUT THIS PROSPECTUS ​ ​ ​ ​ 1 ​ ​ FORWARD-LOOKING STATEMENTS ​ ​ ​ ​ 2 ​ ​ PROSPECTUS SUMMARY ​ ​ ​ ​ 3 ​ ​ INFORMATION INCORPORATED BY REFERENCE ​ ​ ​ ​ 4 ​ ​ WHERE YOU CAN FIND MORE INFORMATION ​ ​ ​ ​ 5 ​ ​ Risk Factors ​ ​ ​ ​ 6 ​ ​ USE OF PROCEEDS ​ ​ ​ ​ 7 ​ ​ DESCRIPTION OF DEBT SECURITIES ​ ​ ​ ​ 8 ​ ​ PLAN OF DISTRIBUTION ​ ​ ​ ​ 10 ​ ​ LEGAL MATTERS ​ ​ ​ ​ 12 ​ ​ EXPERTS ​ ​ ​ ​ 12 ​ ​ S-i TABLE OF CONTENTS ​ ABOUT THIS PROSPECTUS SUPPLEMENT On February 14, 2025, we filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 utilizing a shelf registration process relating to the securities described in this prospectus supplement, which became effective upon filing. This document is in two parts. The first part is the prospectus supplement, which describes the specific terms of the Notes the Issuer is offering and certain other matters relating to the Issuer. The second part, the accompanying prospectus, gives more general information about debt securities that the Issuer may offer from time to time, some of which may not apply to the Notes the Issuer is offering. The rules of the SEC allow us to incorporate by reference information into this prospectus supplement. This information incorporated by reference is considered to be a part of this prospectus supplement, and information that we file later with the SEC, to the extent incorporated by reference, will automatically update and supersede this information. See “ Information Incorporated by Reference .” You should read this prospectus supplement along with the accompanying prospectus, as well as the documents incorporated by reference. If the description of the offering varies between this prospectus supplement and the accompanying prospectus, you should rely on the information in this prospectus supplement. We have not, and the underwriters have not, authorized any d